摘要
目的:观察糖克软胶囊治疗2型糖尿病气阴两虚证的临床疗效。方法:采取随机、双盲、安慰剂设计,试验组给予糖克软胶囊(0.2g/粒),1粒/次,1日2次(早晚各一次);对照组给予安慰剂软胶囊(0.2g/粒),1粒/次,1日2次(早晚各一次),均于餐前口服。疗程为84天,观察糖化血红蛋白、血糖、中医证候、胰岛素敏感性指标及血脂变化情况。结果:糖克软胶囊具有降低糖化血红蛋白的作用,与对照组比较差异有统计学意义;同时对血糖(FPG、2hPG)和糖负荷后曲线下面积(AUCG)、中医证候、胰岛素敏感性指标(ISI)、血脂(TG、TC、HDL-C、LDL-C)具有一定作用,但与对照组比较,差异均无统计学意义。结论:糖克软胶囊具有降低2型糖尿病-气阴两虚证患者糖化血红蛋白的作用,值得进一步研究。
To evaluate Tangke intervention blood glucose control in type 2 diabetes ( Qi Deficiency) safety and effectiveness. Meth- ods: The 40 cases of type 2 diabetes ( TCM Syndrome is a Qi and Yin deficiency) were randomly divided into 2 groups by a randomized, double-blind, placebo design. There were 20 cases in the experimental group by taking oral of Tangke capsules (0.2g / tablets, 1 tablet/ times,2 times/day) ,and the other 20 cases in control group by taking oral of placebo (0.2g/tablets, 1 tablet/times,2 times/day). The courses of the treatment were 84 days. Results: The test screening a total of 45 subjects were randomized to dO cases, 36 cases included in the FAS analysis, and experimental group of 18 cases, 18 cases in the control group; included in the PPs analysis of 34 cases, the experi- mental group of 17 cases in the control group 17 cases; 37 cases completed the study, completed the trim of three cases, the experimental group off two cases of the control group, shedding one cases. Excluding the three cases, which test group 1 patients in the control group 2 ca- ses. With the advance of treatment time, Primary efficacy endpoint of glycosylated hemoglobin test group and control group to improve the de- gree of FAS analysis difference was statistically significant (P 〈 0.05 ), secondary outcome measures glucose (FPG, 2hPG) and glucose load after the area under the curve (AUCG), TCM syndrome, insulin sensitivity index (ISI), lipids (TG,TC, HDL-C, LDL-C) comparison showed no significant difference (P 〉 0.05), by FAS and the PP analysis. Conclusion: Though the effections of Tangke on glucose, lip- ids, insulin sensitivity index of TCM syndrome intervention is not obvious, but the index of HbA1C improved, but the curative effects to need further clinical study.
出处
《中药药理与临床》
CAS
CSCD
北大核心
2012年第6期129-131,共3页
Pharmacology and Clinics of Chinese Materia Medica
基金
国家重大新药创制课题(NO.201207230001)
上海市科委项目(NO.09dz1970600)